Ra Pharma Aims For Oral Peptide Drugs Using Synthetic Amino Acids
This article was originally published in The Pink Sheet Daily
Executive Summary
Just out of stealth mode, privately held biotech closes second tranche of $27 million Series A financing and announces first drug program will pursue an oral kallikrein inhibitor for prevention of hereditary angioedema.
You may also be interested in...
Ra Pharma’s Cyclomimetic Technology To Help Merck With Difficult Targets
In its first partnership, Ra, focused on solutions for intracellular protein-protein reactions, could earn up to $200 million by helping Merck to discover and develop drug candidates for protein targets in several undisclosed therapeutic areas.
Shire To Test Convenience Versus Familiarity In HAE With Approval Of Firazyr
FDA’s Aug 25 approval of Shire PLC’s Firazyr (icatibant) for acute treatment of attacks of hereditary angioedema, with a label that allows patients to self-administer the drug, puts a convenience advantage up against a first-to-market advantage for the well-established C-1 esterase inhibitors.
Peptide Therapeutics' Rising Tide
As emerging technologies begin to overcome peptide therapeutics’ pharmacologic limitations, their compelling potential grows clearer and their deal value has grown. Most if not all of Big Pharma and Big Biotech now have rebuilt their internal peptide drug development programs and show interest in start-ups with peptide pipelines and platforms.